Gene fusion detection is required for a comprehensive somatic tumor profile with associated treatment selection options. After evaluating the analytical validity of multiple gene fusion detection methods, the Archer FusionPlex Solid Tumor Panel was found to complement the JAX Cancer Treatment Profile™ (JAX-CTP) clinical test in terms of workflow, specimen requirements and turnaround time. This webinar outlines the clinical validation of the incorporation of FusionPlex Solid Tumor Panel into the JAX-CTP test system, including key steps in that process:
Honey V. Reddi, Ph.D., FACMG, is the Clinical Lab Director at The Jackson Laboratory in Farmington, CT. Prior to her current role, Dr. Reddi held positions of Vice President of Clinical Operations and the Laboratory Director at Transgenomic, Inc., Clinical Molecular Geneticist & Director - Sales and Marketing at Prevention Genetics, and Assistant Professor of Medicine in the Division of Endocrinology at the Mayo Clinic.
Dr. Reddi received her Ph.D. in Biotechnology from the International Center for Genetic Engineering & Biotechnology at Hamdard University in New Delhi, India followed by training in clinical molecular genetics at the Mayo Clinic.
She has 20 years of experience in molecular genetics with expertise in cancer biology, viral-based therapies and clinical diagnostics for somatic and inherited disorders. Dr. Reddi is certified by the American Board of Medical Genetics in clinical molecular genetics and is a fellow of the American College of Genetics and Genomics.
2477 55th Street, Suite 202
Boulder, CO 80301